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Most cases of invasive meningococcal disease occur in immunocompetent chil-
dren and young adults. Serogroup B accounts for most cases in Europe followed
by serogroup C, while serogroups W and Y are uncommon. We describe a case
of recurrent invasive meningococcal disease (IMD) caused by two different
serogroups in a 16-year-old boy with complement deficiency. All tested cultures
were negative, but PCR from blood was positive in both episodes. Our patient
gradually recovered without sequelae. This case report emphasizes also the
need to provide appropriate chemoprohylaxis and/or immunoprophylaxis to
certain individuals. 
Prikaz bolesnika
Ve}ina slu~ajeva invazivne meningokokne bolesti pojavljuje se u imunokompe-
tentne djece i mladih odraslih. Serogrupa B naj~e{}a je u Europi, potom slijedi
serogrupa C dok su serogrupe W i Y rijetke. Ovdje opisujemo rekuriraju}u in-
vazivnu meningokoknu bolest uzrokovanu s dvije razli~ite serogrupe u {es-
naestogodi{njeg dje~aka s deficijencijom komplementa. Sve testirane hemokul-
ture bile su negativne, ali je PCR metodom iz krvi dokazan uzro~nik u obje epi-
zode. Na{ bolesnik se postupno oporavio bez posljedica. Ovim prikazom
bolesnika isti~emo zna~aj primjene odgovaraju}e kemoprofilakse i/ili imuno-
profilakse u odre|enih osoba.
Introduction
Neisseria meningitidis (N. menigitidis) is a Gram-neg-
ative, strictly human respiratory transmitted bacterium
causing invasive meningococcal disease (IMD), with
most cases occurring in the winter. Serogroup B domi-
nates in Croatia as elsewhere in Europe, followed by
serogroup C, while serogroups W and Y are uncommon.
In some European countries, there is a decline in IMD cas-
es caused by serogroup C in adolescents due to implemen-
tation of routine vaccination against meningococci of this
serogroup, leading to a reduction in the number of healthy
carriers as well as the incidence of IMD, with consequent
emergence of collective immunity[1, 2, 3].
Most cases of IMD occur in immunocompetent chil-
dren and young adults. Underlying immune defects that
confer a predisposition to IMD include functional or
anatomical asplenia, a deficiency of properdin, and a defi-
ciency of terminal complement components [4]. 
Culture is the gold standard in confirmation and char-
acterization of N. meningitidis. However, the diminished
sensitivity of the cerebrospinal fluid (CSF) culture in pa-
tients who received antibiotics before the lumbar puncture
(LP) hinder clinicians from reaching a prompt diagnosis
and starting the treatment in the ideal period. Non-culture
molecular standardized methods, such as the real-time
polymerase chain reaction (PCR) or multiplex PCR, are
now essential tools and almost "new gold standard" in mi-
crobiological diagnostics of IMD for detecting microor-
ganisms in the CSF with high sensitivity and specificity
[5, 6]. In the European Union, 25 % of cases are confirmed
by PCR alone. In the United Kingdom and Ireland, this
rises to around 50 %. In the United States, the Center for
Disease Control and Prevention (CDC) only recently in-
cluded PCR as confirmatory in its case definition. There is
yet no international consensus on their use, although PCR
methods incorporating a number of targets have been de-
veloped [7].
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white blood cell (WBC) count of 26.4 × 109/L with 85 %
neutrophils and blood platelet count of 123.0 × 109/L.
Glucose in blood was 4.6 mmol/L and serum creatinine
was 133.0 umol/L. Coagulation tests included: prothrom-
bin time of 0.6, fibrinogen levels of 5.8 g/L and D-dimers
of more than 4.4 mg/L. Emergency CT of the head showed
an arachnoid cyst of the left middle cranial fossa with di-
mensions 42 × 20mm (Galassi 1) that compressed left tem-
poral parenchyma along with oedema of the right maxil-
lary sinus mucosa – acute sinusitis. The rest of the CT ex-
am was unremarkable. CSF findings included WBC count
of 17920 cells/mm3 (78 % polymorphonuclears, 22 %
mononuclears) – 76 % neutrophils, 7 % lymphocytes, 8 %
monocytes; protein levels of 2.7 g/L,  glucose of 1.4
mmol/L, lactate was 10.9 mmol/L and chloride ions were
120.0 mmol/L.
N. meningitidis was not found in blood cultures, na-
sopharyngeal and pharyngeal swab culture or in CSF cul-
ture. However, PCR for N. meningitides in blood came
back positive for serogroup Y. Chest X-ray, thoracic and
abdominal ultrasound showed normal findings. Electro-
encephalography (EEG) showed diffuse irregularity. 
The patient received intravenous ceftriaxone 2 × 2 g for
10 days and mannitol 10 % solution during 5 days. His
close contacts (family members) prophylactically re-
ceived one tablet of ciprofloxacin 500 mg. 
Nine months later, in the middle of February, he was
readmitted with a similar, but slightly milder clinical pre-
Cefotaxime, ceftriaxone, and penicillin during a 7 to
10 day course, are preferred as initial intravenous therapy
in patients with a clinical diagnosis of IMD. 
The efficacy of conjugated anti-meningococcal vac-
cines is greater than 95 % and indicates a protective effect
on the unvaccinated when high vaccine coverage is
reached in the population (collective immunity) [1]. Early
in 2013, the European Commission approved the four-
component protein meningococcal serogroup B (4CMenB)
vaccine, "Bexsero". This and the bivalent recombinant
lipoprotein vaccine, "Trumenba", have subsequently been
used prior to licensure in the United States as a respond to
outbreaks of serogroup B disease among university stu-
dents [1].
We describe a case of recurrent IMD caused by two
different serogroups in a 16-year-old boy with comple-
ment deficiency. This case report emphasizes the need to
provide appropriate chemoprohylaxis and/or immunopro-
phylaxis to certain individuals.
Case report
At the end of May, a 16-year-old boy from Zagreb was
transferred to the University Hospital for Infectious
Diseases from another hospital in Zagreb as suspected
bacterial meningitis. Upon suspicion for IMD, the patient
received one dose of ceftriaxone intravenously before ad-
mission to our hospital. 
He had fever lasting for two days, occipital headache
and sore throat with cough. He vomited in 3 occasions and
in the last 24 hours he had had at least 3 liquid stools. He
complained of intense pain in his legs. He had been previ-
ously healthy except from asthma for which he was taking
daily therapy (fluticasone and salbutamol inhalations).
His father had diabetes mellitus, his mother had asthma
and his three siblings were all healthy. They lived in a flat
in Zagreb where he attended the second grade of an indus-
trial trade school. He negated animal contact, tick bites
and international travels. 
At admission, his blood pressure was 110/60 mmHg,
heart rate 70/min, temperature 37.3 °C, respiratory rate
15/min, Glasgow coma scale 13 and oxygen saturation
100 %. He was somnolent, but well oriented, afebrile after
antipyretic medications, with diminished appearance and
difficulty walking. Meningeal sings were positive. His
skin was without rash or signs of bleeding except for one
painless necrotic-haemorrhagic skin lesion 3 × 3 cm with
red outer layer, above skin surface, located in his parietal
scalp area left (Figure 1.). Petechial haemorrhages were
noted on the soft palate. Further physical examination was
unremarkable. 
Laboratory data on admission included: C-reactive
protein of 285.8 mg/L, serum procalcitonin of 19.7μg/L,
Figure 1. Localised necrotic-haemorrhagic skin lesion in the pa-
tient's left parietal scalp area (3 × 3cm)
Slika 1. Lokalizirana nekroti~na-hemoragi~na ko`na lezija u
lijevom parietalnom podru~ju skalpa (3 × 3cm)
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sentation of fever, headache and leg pain. At admission his
vital signs were normal, he was conscient and well orient-
ed. Meningeal signs were negative. He had skin erythema
of the abdomen and lower legs without signs of haemor-
rhagic rash. Herpes labialis of the upper lip was noted as
well as trismus (mostly because of the neck pain upon
opening the mouth). Further physical examination was
unremarkable. 
Laboratory findings on admission included: C-reac-
tive protein of 37.7 mg/L, serum procalcitonin of 15.6
μg/L, WBC count of 8.2 × 109/L with 94 % neutrophils,
blood platelet count of 178.0 × 109/L, prothrombin time of
0.7, fibrinogen levels of 3.4 g/L and D-dimers of 4.5
mg/L. PCR for N. meningitidis in blood was repeated and
came back positive for serogroup W. Again, all taken cul-
tures were negative although the patient did not receive
prior treatment. Later immunological laboratory tests –
IgA, IgM, IgG and flow cytometry – came back all within
normal range. The investigation for complement parame-
ters discovered deficient alternative pathway activity, de-
creased classical and lectin pathway activities. The level
of antigenic factor I was decreased. The levels of C3, C1q,
C4 and factor B antigen and factor H were within normal
range. Complement activation product levels were in nor-
mal range. EEG showed normal finding. 
The patient received intravenous ceftriaxone 2 × 2 g for
7 days, recovered fully and was discharged from the hos-
pital. As chemoprohpylaxis he received phenoxymethyl-
penicillin 2 × 1 500 000 IU until he will be vaccinated with
"Bexsero" and "Trumenba". 
Discussion
We report a case of a 16-year-old patient with comple-
ment deficiency who presented with meningococcal
meningitis and sepsis caused by serogroup Y and nine
months later with meningococcal septicaemia caused by
serogroup W. Discovering arachnoid cyst by accident in
our patient was not related to presenting symptoms in any
of the two IMD episodes. In Europe, both serogroups Y
and W are uncommon; however, serogroup W is increas-
ing consistently from 2011, while serogroup Y remains
stable [8]. In our patient, all tested cultures came back
negative, but PCR from blood came back positive in both
IMD episodes. The known limitations of culture, such as
poor sensitivity, time dependence, and false-negative re-
sults under antibiotic therapy require the development of
rapid reliable methods of pathogen identification such as
PCR-based diagnostics. Under clinical conditions, PCR
requires less time than culture-based methods for identifi-
cation of causative pathogens from blood in patients with
IMD [9]. PCR-based methods are not at risk from loss of
viable organisms through early antibiotic treatment and
sample processing. However, contamination is a problem
of PCR-based diagnostic methods, since they detect the
pathogens only if specific DNA segments are present,
even from non-viable or already phagocytized pathogens
[9]. The production of false positives due to contamina-
tion should be avoided by strict adherence to procedural
guidelines. The general trend has been to include PCR as
confirmatory in case definitions globally, although there
is still some controversy on this point. 
We confirmed complement deficiency in our patient.
Testing for complement deficiencies in Neisseria infec-
tions is normally recommended in the case of a family his-
tory, a rare serotype, or when recurrent and systemic in-
fections occur [3]. Our patient presented as recurrent sys-
temic IMD caused by rare serogroups (for this part of the
world) and therefore indicated further complement para-
meters investigation. Complement deficiencies (of both
terminal and initial fractions) are associated with an in-
creased susceptibility to the IMD. In such patients, the use
of vaccinations (if possible conjugated) against pneumo-
coccus, meningococcus and haemophilus could prevent
further invasive diseases. Our patient gradually recovered
without sequelae. 
In conclusion, recurrent IMD is rare. In such case, one
must consider complement deficiency or other immune
defects as an underlying condition. PCR might have some
advantages over culture in the identification of causal
pathogens from blood samples. This might influence the
impact of PCR-based methods in the identification of
causal septic pathogens in clinical routine. There are
widely available proper regimens for eradication of na-
sopharyngeal carriage and chemoprophylaxis of close
contacts with a case of IMD; however, there are no clear
objectives on how to prevent recurrent IMD. As a measure
of secondary prevention our patient did not receive treat-
ment after the first episode, but has received phenoxy-
methylpenicillin after the second episode of IMD. Several
vaccines targeting different serogroups are available for
the prevention of invasive meningococcal disease.
Croatia does not have yet anti-meningococcal vaccines
listed in routine national immunization programme and
cases like this urge on considering it as an option.
Continued strengthening of surveillance for IMD is essen-
tial to evaluate the impact of ongoing immunisation pro-
grammes and to support decision-makers in view of the
availability of new vaccines. 
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